Martin-Martin LS et al. has shown in an open randomized active controlled clinical trial the activity of low-dose SKA IL-4, IL-10, and Ab anti IL-1 versus DMARDs in maintaining low disease activity in patients affected by rheumatoid arthritis in remission after therapy with biological drugs [32]. This evidence concerns the gene IL4 and rheumatoid arthritis.